Photocure ASA is a Norwegian pharmaceutical company listed on Oslo Stock Exchange (PHO). The company develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technology, targeting key dermatology and oncology markets.
- Focus : Manufacturer
- Industry : Pharma
News about PhotoCure
09-Jul-2012 | people
Photocure appoints Chief Financial Officer
Photocure ASA announced the appointment of Erik Dahl to its management team as the Chief Financial Officer, effective 15 August 2012.Dahl joins Photocure ...
12-Jun-2012 | research and development
Photocure announces positive results of Phase 2B study evaluating Visonac in acne
Photocure ASA announced the results of the phase 2b study in acne with Visonac (methyl aminolevulinate 80mg/g), a topical acne treatment. In this study, ...
07-Mar-2012 | research and development
Photocure announces the achievement of the second transition milestone of EUR 1.5 million for Hexvix
Photocure ASA announced the achievement of the second manufacturing transition milestone from Ipsen, its new strategic partner for commercializing Hexvix ...
11-Jan-2012 | people
Photocure strengthens its management team
Photocure ASA announces the appointment of Ambaw Bellete to its management team, as the Head US Cancer Commercial Operations.In his new role, Ambaw will ...
13-Oct-2011 | research and development
Photocure announces the achievement of the first transition milestone for Hexvix
Photocure ASA announced the achievement of the first transition milestone from Ipsen, its new strategic partner for commercializing Hexvix worldwide, ...
21-Jun-2011 | research and development
Photocure initiates enrolment into phase II trial of Cevira® for cervical HPV infection
First study to evaluate optimal dose of novel integrated drug-delivery device
16-May-2011 | research and development
Photocure: Hexvix/Cysview demonstrates long term benefit
Results from 5.5 year follow up of recurrence of bladder cancer